BBR 3464: A novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2626-2634

  Manzotti, Carla ^a   Pratesi, Graziella ^b   Menta, Ernesto ^a   Di Domenico, Roberto ^a   Cavalletti, Ennio ^a   Fiebig, Heinz H ^c   Kelland, Lloyd R ^d   Farrell, Nicholas ^e   Polizzi, Donatella ^b   Supino, Rosanna ^b   Pezzoni, Gabriella ^a   Zunino, Franco ^b  

^a Novuspharma SpA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF FREIBURG   (Germany)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BBR 3464; CISPLATIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CHEMOSENSITIVITY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; MELANOMA; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; CELL CYCLE; CELL SURVIVAL; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MELANOMA; MICE; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0033924880     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kelland, L. R. New platinum antitumor complexes. Crit. Rev. Oncol.-Hematol., 15: 191-219, 1993.
2. Harrap, K. R. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev., 12: 21-33, 1985.
3. Pratesi, G. Preclinical studies of cisplatin analogs. Inorganica Chimica Acta, 137: 35-38, 1987.
4. Raymond, E., Chaney, S. G., Taamma, A., and Cvitkovic, E. Oxaliplatin: a review of preclinical and clinical studies. Ann. Oncol., 9: 1053-1071, 1998.
5. Lebwohl, D., and Canetta, R. Clinical development of platinum complexes in cancer therapy: a historical perspective and an update. Eur. J. Cancer, 34: 1522-1534, 1998.
6. Farrell, N. Nonclassical platinum antitumor agents: perspectives for design and development of new drugs complementary to cisplatin. Cancer Invest., 11: 578-589, 1993.
7. Qu, Y., Bloemink, M. J., Reedijk, J., Hambley, T. W., and Farrell, N. Dinuclear platinum complexes form a novel intrastrand adduct with d(GpG), an anti-syn conformation of the macrochelate as observed by NMR and molecular modeling. J. Am. Chem. Soc., 118: 9307-9313, 1996.
8. Kasparkova, J., Mellish, K. J., Qu, Y., Brabec, V., and Farrell, N. Site-specific d(GpG) intrastrand cross-links formed by dinuclear platinum complexes: bending and NMR studies. Biochemistry, 35: 16705-16713, 1996.
9. Farrell, N. DNA binding of nonclassical platinum antitumor complexes. In: L. H. Hurley and S. B. Chaires (eds.), Advances in DNA Sequence-Specific Agents, Vol. 3, pp. 179-199. New Haven: JAI Press Inc., 1998.
10. Brabec, V., Kasparkova, J., Vrana, O., Novakova, O., Cox, J. W., Qu, Y., and Farrell, N. DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent. Biochemistry, 38: 6781-6790, 1999.
11. Pratesi, G., Perego, P., Polizzi, D., Righetti, S. C., Supino, R., Caserini, C., Manzotti, C., Giuliani, F. C., Pezzoni, G., Tognella, S., Spinelli, S., Farrell, N., and Zunino, F. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Br. J. Cancer, 80: 1912-1919, 1999.
12. Perego, P., Caserini, C., Gatti, L., Carenini, N., Romanelli, S., Supino, R., Colangelo, D., Viano, I., Leone, R., Spinelli, S., Pezzoni, G., Manzotti, C., Farrell, N., and Zunino, F. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol. Pharmacol., 55: 528-534, 1999.
13. Supino, R., Mapelli, E., Sanfilippo, O., and Silvestro, L. Biological and enzymatic features of human melanoma clones with different invasive potential. Melanoma Res., 2: 377-384, 1992.
14. Kelland, L. R., Mistry, P., Abel, G., Loh, S. Y., O'Neill, C. F. Murrer, B. A., and Harrap, K. R. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res., 52: 3857-3864, 1992.
15. Kelland, L. R., Barnard, C. F. J., Mellish, K. J., Jones, M., Goddard, P. M., Valenti, M., Bryant, A., Murrer, B. A., and Harrap, K. R. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity. Cancer Res., 54: 5618-5622, 1994.
16. Boyd, M. R. The future of new drug development. In: J. E. Neiderhuber (ed.), Current Therapy in Oncology, pp. 11-22. Philadelphia: B. C. Decker, Inc., 1993.
17. Supino, R., Righetti, S. C., Magnani, I., Bottiroli, G., and Prosperi, E. Modulation and cell cycle distribution of mutant p53 protein in a human small-cell lung carcinoma cell line after exposure to cytotoxic agents. Cell. Pharmacol., 3: 253-260, 1996.
18. Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., and Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst., 81: 1088-1092, 1989.
19. Loh, S. Y., Mistry, P., Kelland, L. R., Abel, G., and Harrap, K. R. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br. J. Cancer, 66: 1109-1115, 1992.
20. Aebi, S., Kurdi-Haidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R. D., Boland C. R., Koi, M., Fishel, R., and Howell, S. B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res., 56: 3087-3090, 1996.
21. Perego, P., Zunino, F., Carenini, N., Giuliani, F., Spinelli, S., and Howell, S. B. Sensitivity to cisplatin and platinum-containing compounds of Schizosaccharomyces pombe rad mutants. Mol. Pharmacol., 54: 213-219, 1998.
22. Zunino, F., Perego, P., Pilotti, S., Pratesi, G., Supino, R., Arcamone, F. Role of apoptotic response in cellular resistance to cytotoxic agents. Pharmacol. Ther., 76: 177-185, 1997.
23. Investigator's Brochure for the Investigational New Drug: BBR 3464. Ed. 5. Novuspharma S.p.A., Milan: 2000.